Advanced Search
Share
January - February 2010 Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents...
Journal Information
Previous article | Next article
Vol. 14. Issue 1.
Pages 60-65 (January - February 2010)
Export reference
Share
Share
Print
Download PDF
More article options
Statistics
Vol. 14. Issue 1.
Pages 60-65 (January - February 2010)
Original article
DOI: 10.1016/S1413-8670(10)70012-X
Open Access
Seroprevalence of hepatitis B and hepatitis C markers among children and adolescents in the south brazilian region - metropolitan area of Florianópolis, Santa Catarina
Visits
2278
Download PDF
Andréia Royer Voigt1, Miguel Strazer Neto2, Celso Spada1, Arício Treitinger1,
Corresponding author
aricio@ccs.ufsc.br

Correspondence to: Dr. Arício Treitinger Universidade Federal de Santa Catarina, Health Science Center, Clinical Analysis Department, Campus Universitário Trindade, Florianópolis – SC88010- 970 – Brazil. Phone: +55 (48) 3721 9712. Fax: +55 (48) 3721 9542.
1 Clinical Analysis Department, Health Sciences Center, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil
2 Hospital of Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina, Brazil
This item has received
2278 Visits

Under a Creative Commons license
Article information
Statistics
Abstract

Hepatitis B and C are important causes of morbidity and mortality worldwide. In Brazil, according to the Ministry of Health, about 15% of population is infected by hepatitis B virus (HBV) and less than 1% by hepatitis C virus (HCV). Nevertheless, the age-specific prevalence of HBV and HCV markers remains unknown. This study aimed to determine the seroprevalence of HBV and HCV markers of infection and immunity in children and adolescents between 10 to 16 years old who live in the metropolitan area of Florianópolis, state of Santa Catarina, South of Brazil. Three hundred and eighty four individuals were enrolled in this study. Serological markers for HBV and HCV (HBsAg, total anti-HBc, anti-HBc IgM, anti-HBs and anti-HCV) were determined through Microparticle Enzyme Immunosorbant Assay (MEIA) - AxSYM System® - by using commercial diagnostic kits (Abbott Laboratories, Abbott Park, Illinois, USA). All 384 adolescents (100%) were negative for HBsAg and anti-HBc IgM. Only two (0.52%) were positive for total anti-HBc. Among the studied individuals, 226 (58.85%) presented titers of anti-HBs≥10.0mIU/mL, 121 (31.51%) presented anti HBs < 10.0mIU/mL, and 37 (9.64%) did not present titers of anti-HBs. Regarding to anti-HCV, all 384 adolescents (100%) presented negative results for this marker. In conclusion, this study showed a low prevalence of HBV and HCV infections. In addition, it was verified a great number of children and adolescents (89.84%) who were positive for the immunity marker anti-HBs, implying that the National Immunization Program Protocol for hepatitis B has been effective in the studied region.

Keywords:
HBV
HCV
HBsAg
anti-HBs
anti-HBc
anti-HCV
seroprevalence
Full text is only aviable in PDF
References
[1.]
B. Rehermann, M. Nascimbeni.
Immunology of hepatitis B virus and hepatitis C virus infection.
Nat Rev Immunnol, 5 (2005), pp. 215-229
[2.]
W.W. Bond, N.J. Petersen, M.S. Favero.
Viral hepatitis B: aspects of environmental control.
Health Lab Sci, 14 (1977), pp. 235-252
Medline
[3.]
M.J. Alter, H.S. Margolis.
The emergence of hepatitis B as a sexually transmitted disease.
Med Clin North Am, 74 (1990), pp. 1529-1541
Medline
[4.]
V. Tahan, C. Karaca, B. Yildirim, et al.
Sexual transmission of HCV between spouses.
Am J Gastroenterol, 100 (2005), pp. 821-824
http://dx.doi.org/10.1111/j.1572-0241.2005.40879.x | Medline
[5.]
D.M. Parkin, F. Bray, J. Ferlay, P. Pisani.
Estimating the world cancer burden: Globocan 2000.
Int J Cancer, 94 (2001), pp. 153-156
Medline
[6.]
G. Fattovich, T. Stroffolini, I. Zagni, F. Donato.
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Gastroenterology, 127 (2004), pp. S35-S50
Medline
[7.]
World Health Organization. Programmes and projects - Immunization service delivery and accelerated disease control – New vaccines and technologies - Hepatitis B. 2008.(http://www.who.int/immunization_delivery/new_vaccines/hepb/en/index.html).
[8.]
World Health Organization. Programmes and projects – Media centre - Fact sheet n° 164 - Hepatitis C. 2000. (http://www.who.int/mediacentre/factsheets/fs164/en/).
[9.]
Hepatite B: Glossário de doenças. Programa Nacional de Hepatites Virais. (http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt=27151) (in portuguese).
[10.]
Hepatite C: Glossário de doenças. Programa Nacional de Hepatites Virais. (http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt=27220) (in portuguese).
[11.]
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Material instrucional para capacitação em vigilância epidemiológica das hepatites virais. Brasília, DF: Ministério da Saúde, 2008.(in portuguese).
[12.]
J.H. Chávez, S.G. Campana, P. Haas.
Panorama de hepatite B no Brasil e no Estado de Santa Catarina.
Rev Panam Salud Publica, 14 (2003), pp. 91-96
Medline
[13.]
L.V.G. Miranda, A.D.C. Passos, J.F.C. Figueiredo, et al.
Marcadores sorológicos de hepatite B em indivíduos submetidos a exames de sangue em unidades de saúde.
Journal of Public Health, 34 (2000), pp. 286-291
Medline
[14.]
A.F.B. Andrade, M.O. Silva, S.G.C. Silva, et al.
Seroprevalence of hepatitis B and C virus markers among blood donors in Rio de Janeiro, Brazil, 1998-2005.
Mem Inst Oswaldo Cruz, 101 (2006), pp. 673-676
Medline
[15.]
M.C. Nascimento, P. Mayaud, E.C. Sabino, et al.
Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey.
J Med Virol, 80 (2008), pp. 53-57
http://dx.doi.org/10.1002/jmv.21046 | Medline
[16.]
A. Treitinger, C. Spada, L.A.P. Ferreira, et al.
Hepatitis B and hepatitis C prevalence among blood donors and HIV-1 infected patients in Florianópolis-Brazil.
Braz J Infect Dis, 4 (2000), pp. 192-196
Medline
[17.]
N. Rosini, D. Mousse, C. Spada, A. Treitinger.
Seroprevalence of HBsAg, anti-HBc and anti-HCV in Southern Brazil, 1999-2001.
Braz J Infect Dis, 7 (2003), pp. 262-267
Medline
[18.]
A. Treitinger, C. Spada, E.L. Silva, et al.
Prevalence of serologic markers of HBV and HCV infection in HIV-1 seropositive patients in Florianópolis-Brazil.
Braz J Infect Dis, 3 (1999), pp. 1-5
Medline
[19.]
R.A.R.A. Pereira, A.D.H. Mussi, V.C.A. Silva, F.J.D. Souto.
Hepatitis B virus infection in HIV-positive population in Brazil: results of a survey in the state of Mato Grosso and a comparative analysis with other regions of Brazil.
BMC Infect Dis, 6 (2006), pp. 34
http://dx.doi.org/10.1186/1471-2334-6-34 | Medline
[20.]
Motta VT, Wagner MB. Bioestatística. Caxias do Sul, RS: Educs; São Paulo, SP: Robe Editorial, 2003.(in portuguese).
[21.]
T.R. Silveira, J.C. Fonseca, L. Rivera, et al.
Hepatitis B seroprevalence in Latin America.
Pan Am J Public Health, 6 (1999), pp. 378-383
[22.]
Inquérito nacional de hepatites virais. 2009. (http://www.hepto.com) (in portuguese).
[23.]
Centers for Disease Control.
Recommendation of the Immunization Practices Advisory Committee (ACIP). Recommendations for protection against viral hepatitis.
Morb Mortal Wkly Rep, 34 (1985), pp. 313-324
[24.]
Centers for Disease Control.
Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention.
Morb Mortal Wkly Rep, 38 (1987), pp. 353-360
[25.]
International Group.
Immunization against hepatitis B.
Lancet, 1 (1988), pp. 875-876
Medline
[26.]
D.J. West, G.B. Calandra.
Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.
Vaccine, 14 (1996), pp. 1019-1027
Medline
[27.]
J. Banatvala, P. Van Damme, S. Oehen.
Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.
Vaccine, 19 (2001), pp. 877-885
Medline
[28.]
R.X. Wang, G.J. Boland, J.V. Hattum, G.C. De Gast.
Long term persistence of T cell memory to HBsAg after hepatitis B vaccination.
World J Gastroenterol, 10 (2004), pp. 260-263
Medline
[29.]
B.J. McMahon, D.L. Bruden, K.M. Petersen, et al.
Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up.
Ann Intern Med, 142 (2005), pp. 333-341
Medline
[30.]
C.M. Dentinger, B.J. McMahon, J.C. Butler, et al.
Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth.
Pediatr Infect Dis J, 24 (2005), pp. 786-792
Medline
[31.]
A.R. Zanetti, A. Mariano, L. Romanò, et al.
Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Lancet, 366 (2005), pp. 1379-1384
http://dx.doi.org/10.1016/S0140-6736(05)67568-X | Medline
[32.]
C.T. Ferreira, T.R. Silveira.
Viral hepatitis prevention by immunization.
J. Pediatr, 82 (2006), pp. S55-S66
[33.]
C. Giambi, A. Bella, A. Barale, et al.
A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines.
BMC Infect Dis, 8 (2008), pp. 100
http://dx.doi.org/10.1186/1471-2334-8-100 | Medline
[34.]
S.R. Bialek, W.A. Bower, R. Novak.
Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis b vaccine beginning at birth: a 15-year follow-up study.
Pediatr Infect Dis J, 27 (2008), pp. 881-885
http://dx.doi.org/10.1097/INF.0b013e31817702ba | Medline
[35.]
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Sistema nacional de vigilância em saúde: relatório de situação - Santa Catarina. Brasília, DF: Ministério da Saúde, 2007 (in portuguese).
[36.]
R. Focaccia, O.J. Conceição, H.J. Sette, et al.
Estimated prevalence of viral hepatitis in general population of the municipality of São Paulo, measured by a serologic survey of a stratified, randomized and residence-based population.
Braz J Infect Dis, 2 (1998), pp. 269-284
Medline
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved

Subscribe to our newsletter

Special content about COVID-19
Recommended
articles
Molecular investigation of occult hepatitis B virus...
Braz J Infect Dis. 2022;26:
Clinical study of hepatitis B vaccine in achieving...
Braz J Infect Dis. 2023;27:
Campylobacter fetus bacteremia complicated by multiple...
Braz J Infect Dis. 2022;26:
Publish in
The Brazilian Journal of Infectious Diseases
The Brazilian Journal of Infectious Diseases
Article options
Tools